Antibody drug conjugates have emerged as a potential option to selectively eliminate the tumor population, with minimal side ...

Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.

Speaking at a recent Technology Networks’ symposium, Dr. Jason Reeves explained how AI is changing the development of ...

A TROP2-directed antibody-drug conjugate, DB-1305/BNT325, demonstrated durable activity in patients with previously treated ovarian cancer in a first-in-human trial. These results were presented at ...

Contract research, development and manufacturing organisation (CRDMO) WuXi XDC Cayman has signed a memorandum of ...

Antibody-drug conjugates (ADCs) are new drugs that combine a monoclonal antibody with a chemotherapy drug. They can specifically target cancer cells to deliver potent chemotherapy drugs.

The theory behind antibody drug conjugates (ADCs) is simple yet elegant: by combining the specificity of a monoclonal antibody with the cytotoxicity of a potent small molecule drug, ADCs can ...

According to preclinical results, the approach combined the benefits of more well-known antibody-drug conjugates (ADCs) with those of immunotherapies. Researchers at The University of Texas MD ...